Sign in
Taking people in NetherlandsPhase 2

Nivolumab and dendritic cell therapy with surgery for peritoneal mesothelioma

Tests nivolumab and dendritic cell therapy alongside surgery in adults with peritoneal mesothelioma.

Key facts

Who runs it
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Where
Rotterdam, NetherlandsSee the site
Registry title
IMMUNOPEC: Combination of neo-adjuvant Checkpoint Inhibition and Dendritic Cell Therapy (MesoPher) with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in patients with Peritoneal Mesothelioma
Status
Recruiting
Phase
Phase 2
People taking part
18 people, planned
Started
1 May 2026
Expected to end
1 Aug 2030
Type of study
Interventional
Record updated
16 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with epithelioid peritoneal mesothelioma who are fit for cytoreductive surgery with heated chemotherapy inside the abdomen (CRS-HIPEC). It tests nivolumab and a dendritic cell vaccine (MesoPher) around this surgery.

Age
18 years or older.
Sex
Men and women can join.
Disease stage
Epithelioid peritoneal mesothelioma confirmed under the microscope. No disease outside the abdomen.
Earlier treatment
No more than 10 mg of prednisolone or equivalent per day, and no other immunosuppressive drugs, in the 6 weeks before the first study drug.

Main reasons for not taking part

  • Cancer spread outside the abdomen
  • Known active serious infection, including HIV, hepatitis B or C, or syphilis
  • Pregnant or breastfeeding women
  • Known allergy to shellfish
  • Serious illness that makes the study treatment too risky

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Histologically confirmed diagnosis of epithelioid peritoneal mesothelioma
  • Patients must be at least 18 years old and must be able to give written informed consent
  • Fit to undergo CRS-HIPEC (as per standard of care of the treating physician/Institution)
  • Ability to return to the study centre for adequate follow-up and vaccinations
  • Written informed consent according to the ICH-GCP
  • Men must be willing to use an effective contraceptive method during the study and for at least 12 months after the last study drug administration
  • Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test just prior to the first study drug administration on day 1, and must be willing to use an effective contraceptive method and for at least 12 months after the last study drug administration

Who cannot take part

  • Use of >10 mg of prednisolone or equivalent/day (or other immunosuppressive agents) during the past 6 weeks before the first study drug administration and throughout the study. Prophylactic usage of dexamethasone (steroids) during chemotherapy is excluded from this 6-week interval. Inhaled or topical steroids, and adrenal replacement steroid ≤10 mg daily prednisone equivalent, are permit-ted in the absence of active autoimmune disease
  • Extra-abdominal metastatic disease
  • Subject with any known active serious infection, including human immunodeficiency virus (HIV), hepatitis B or C virus, or syphilis infection
  • Serious chronic or acute illness with an unwarranted high risk for the study treatment
  • An organic brain syndrome or other significant psychiatric abnormality which would comprise the study
  • Patients with a known allergy to shellfish (may contain KLH)
  • Medical or psychological impediment to probable compliance with the protocol
  • Pregnant or lactating women

Where in Netherlands

  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people

About the trial

What the trial wants to find out

To assess the efficacy of (neo-)adjuvant CPI (nivolumab) and DCT (MesoPher) around CRS-HIPEC.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
IMMUNOPEC: Combination of neo-adjuvant Checkpoint Inhibition and Dendritic Cell Therapy (MesoPher) with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in patients with Peritoneal Mesothelioma
Plain-language title
Nivolumab and dendritic cell therapy with surgery for peritoneal mesotheliomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
16 April 2026